The news comes at the end of a busy year for Cleerly. The company says it will use the funds to grow commercially and generate more evidence in support of its FDA-approved technology.
The scheme took place over a period of at least seven years, resulting in Medicare being billed for more than $70 million in fraudulent claims for unnecessary scans.
